Abstract 1498P
Background
A pilot study has revealed a significant correlation between high levels of circulating HGF and poor response to ICIs therapy in late-stage NSCLC patients treated with ICIs. This study aimed to evaluate the prognostic value and role of the HGF/MET pathway in first-line immunotherapy treatment in advanced NSCLC patients.
Methods
We included 82 consecutive patients, 49 treated with immunotherapy and 33 treated with chemotherapy alone as a group control. We analysed the plasma levels of HGF by ELISA. Immunohistochemistry was used to assess the expression levels of PD-L1, MET, and CD8+ T-Cell infiltration. The contribution of HGF/MET to NSCLC response to ICIs was further investigated by culturing peripheral blood mononuclear cells (PBMC)stimulated with 10 μg/mL phytohemagglutinin (PHA) and/or pembrolizumab (20 nM). The cells were cultured with recombinant HGF or co-cultured with NSCLC patients-derived explants.in the presence of cMET inhibitors Crizotinib or SGX. The immune response was quantified through CD8+ activation and INFγ production.
Results
Correlation tests demonstrated that lower HGF levels were associated with a good response to ICIs (RR=2.143; p=0.004) and low progression (RR=0; p=0.01). Patients with low HGF levels (< Q1) at treatment initiation had longer progression-free survival (PFS) (841 vs 136.5 days; HR = 0.26 95% CI 0.1292-0.5411; p=0.0003) and longer overall survival (OS) (median not reached vs. 489 days; HR 0.36; 95% CI 0.1505-0.8408; p=0.02). Furthermore, when activated PBMCs were cultured in the presence of recombinant HGF or on NSCLC monolayer, the activation/proliferation of CD3+CD8+ lymphocytes, was inhibited, even in the presence of pembrolizumab. The addition of HGF/MET inhibitors (Crizotinib and SGX) suppressed the immunosuppressive properties of recombinant HGF or NSCLC, stimulating INFγ production.
Conclusions
Our study found that high levels of HGF in the peripheral blood are associated with poor response to ICIs, disease progression, and shorter survival in patients with advanced NSCLC. Furthermore, we showed through in vitro experiments that inhibiting the HGF/MET signaling pathway could be a promising therapeutic approach to enhance the efficacy of ICIs in this patient population.
Clinical trial identification
Editorial acknowledgement
Legal entity responsible for the study
University of Paris Saclay, UVSQ.
Funding
Legs Poix Subvention (2018).
Disclosure
E. Giroux-Leprieur: Financial Interests, Personal, Advisory Board: Amgen; Financial Interests, Advisory Board: AstraZeneca, Ipsen, Janssen, Lilly, MSD, Novartis, Pfizer, Sanofi, Takeda. All other authors have declared no conflicts of interest.
Resources from the same session
1535P - Paclitaxel + ramucirumab versus paclitaxel alone in patients with squamous-cell carcinoma of the oesophagus, refractory or intolerant to combination therapy with fluoropyrimidine and platinum-based drugs: Final results from the randomized phase II IKF-S627/RAMOS trial of the AIO
Presenter: Magdalena Scheck
Session: Poster session 21
1536P - HERIZON: A phase II study of HER-Vaxx (IMU-131), a HER2-targeting peptide vaccine plus standard of care chemotherapy in patients with HER2+ advanced stomach cancer - Dose-dependent anti-cancer antibodies correlating with improved clinical outcome
Presenter: Joshua Tobias
Session: Poster session 21
1537P - A phase I study of pevonedistat plus capeOX in patients with advanced gastric cancer refractory to platinum (NCCH-1811)
Presenter: Daisuke Takahari
Session: Poster session 21
1540P - Tislelizumab combined with neoadjuvant chemoradiotherapy for resectable locally advanced oesophageal squamous cell carcinoma: A prospective, phase II clinical study
Presenter: Yi Zhang
Session: Poster session 21
1541P - Neoadjuvant therapy of camrelizumab combined with chemotherapy in patients (pts) with resectable esophageal squamous cell cancer (ESCC)
Presenter: Yinjun Dong
Session: Poster session 21
1542P - Updated results of a phase II clinical trial: Paclitaxel and carboplatin plus PD-1 blockades combined with anlotinib as first-line treatment for advanced oesophageal cancer
Presenter: Mingfang Xu
Session: Poster session 21